Lovly elected to American Society for Clinical InvestigationMay. 4, 2017, 8:50 AM
Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI).
The society, founded in 1908, is home to nearly 3,000 members from the upper ranks of academic medicine and industry.
Lovly is among 64 new ASCI members elected and joins a 2017 class of physician-scientists representing a diverse range of disciplines, specialties and institutions.
“I am honored to be part of this prestigious group which is deeply rooted here at VUMC. I am extremely grateful to our leadership and the ASCI for supporting my nomination and election,” Lovly said.
Lovly manages an active research laboratory at Vanderbilt-Ingram Cancer Center (VICC) and has a special interest in thoracic malignancies. The research is directed at understanding and developing improved therapeutic strategies for clinically relevant molecular subsets of lung cancer.
Lovly received a B.A. in chemistry from Johns Hopkins University in Baltimore, followed by an M.D. and Ph.D. as part of the Medical Scientist Training Program at Washington University in St. Louis.
She completed internal medicine residency and medical oncology subspecialty training at Vanderbilt. During her final year of fellowship, she was the Jim and Carol O’Hare Chief Fellow. She joined the Vanderbilt faculty in the Division of Hematology/Oncology in 2013.
Lovly has received independent grant funding from the Damon Runyon Foundation, Uniting Against Lung Cancer, the V Foundation for Cancer Research, the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the LUNGevity Foundation.
She also serves as co-leader for the Translational Research and Interventional Oncology (TRIO) program in VICC.
She is co-editor for the website www.mycancergenome.org, a Vanderbilt-initiated, freely available website that provides health care practitioners, patients and advocates with up-to-date information regarding genetically informed cancer medicine.